narlumosbart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
narlumosbart

GtoPdb Ligand ID: 13084

Synonyms: Jinlitai® | JMT-103 | JMT103

narlumosbart is an approved drug (China (2023))

Compound class: Antibody

Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.

Summary
Biological activity
Clinical data
References

References
1. Dhillon S. (2024) Narlumosbart: First Approval. Drugs, 84 (1): 105-109. [PMID:38112898]
2. Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q et al.. (2022) Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol, 12: 971594. [PMID:35992822]

References

1. Dhillon S. (2024)
Narlumosbart: First Approval.
Drugs, 84 (1): 105-109. [PMID:38112898]

2. Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q et al.. (2022)
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors.
Front Oncol, 12: 971594. [PMID:35992822]